An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
U.S. regulators in 2026 approved three drugs for weight loss: tirzepatide, semaglutide, and retatrutide. That means these medicines have passed the Food and Drug Administration’s review for safety and effectiveness for treating obesity or excess weight in people who meet certain medical criteria. The approvals let doctors prescribe them for that purpose and often make it easier for insurers to cover the drugs. Semaglutide and tirzepatide you’ve probably heard about because they were already in the headlines for big weight-loss effects. Semaglutide is the active ingredient in brands like Ozempic and Wegovy. It mimics a natural hormone from your gut that tells your brain you’re full and slows how fast food leaves your stomach. Tirzepatide is a newer one that acts on two hormone pathways — think of it as hitting two “fullness” switches instead of one — which tends to produce larger average weight loss in clinical trials. Retatrutide is the newest on the list and works a bit differently: it targets three hormone pathways related to appetite and metabolism (so it’s often described as a “triple” agonist). The clinical trials reported especially large average weight losses compared with older drugs, but those results come from carefully run studies with selected participants and close medical monitoring. Some trials measure outcomes over months to a couple of years; effects and side effects reported in trials don’t always match what happens once a drug is used broadly in the real world. Why it matters: effective medicines for obesity can reduce risks for diabetes, high blood pressure, and heart disease for many people. For someone who has struggled to lose weight with diet and exercise alone, these drugs may offer a tool that produces substantial and sustained weight loss. Broader approval also means more doctors can legally prescribe them and insurers may be more likely to cover treatment, which affects access and cost for patients. There are important caveats and safety issues. These drugs commonly cause nausea, diarrhea, constipation, and other digestive symptoms. Some can affect mood or blood sugar, and the long-term risks over many years aren’t fully known. People with certain medical histories — for example, a personal or family history of some types of thyroid cancer — may be advised not to use them. They typically require ongoing use to maintain weight loss; stopping the drug often leads to some regain. Regulatory approval doesn’t make a medication risk-free, so doctors weigh benefits and harms for each patient. Bottom line: Three powerful new prescription options are now approved for weight loss, offering more effective tools for many people, but they come with side effects, ongoing treatment needs, and still-developing long-term safety data.
Source: polskieradio.pl